NONOF News and Press, Novo-Nordisk A/S From 01/19/24

2024-01-19 08:05:15 ET More on Bristol-Myers, J&J, etc. Johnson & Johnson: Is The Dividend Still Safe After The Kenvue Split-Off? Johnson & Johnson Remains A Safe Bet Amidst Talc Lawsuits And Ambrx Acquisition Bristol-Myers Squibb: Big Dividend Yield, Unl...

2024-01-19 07:59:00 ET Summary Congress passes stopgap spending bill to avert government shutdown and buy more time for funding negotiations. Prices of diabetes drugs Mounjaro and Ozempic see increases, along with hundreds of other drugs. Nasdaq 100 reaches all-time high, driv...

2024-01-16 14:10:03 ET Summary Demand for weight loss drugs and related stocks is high, with companies like Novo Nordisk and Eli Lilly experiencing significant returns. Omega Therapeutics may be a speculative investment opportunity in the weight loss drug market as it recently ent...

2024-01-15 07:30:03 ET Summary GLP-1 weight-loss drugs have little impact on snack companies like PepsiCo, as consumer habits tend to revert to familiar dietary choices. Monster Energy could see increased demand as weight-loss drugs decrease calorie intake and increase the need fo...

2024-01-13 12:05:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. International growth e...

2024-01-12 13:46:01 ET Summary Pfizer Inc. stock has been on a protracted, yearlong decline due to stronger-than-expected normalization in COVID product uptake rates in 2023. But management's conservative 2024 guidance for COVID product revenues sufficiently de-risks for related h...

2024-01-12 11:55:01 ET Summary GLP-1 weight-loss drugs are impacting the pharmaceutical industry and external industries like apparel. Lululemon is expected to benefit from the demand for new clothes as people lose weight. The growing popularity of weight-loss drugs, particula...

2024-01-12 00:25:11 ET Summary Novo Nordisk is the market leader of the fast-growing obesity care industry, which is expected to grow above 20% CAGR until 2030. The company raised three times its guidance during 2023, driven by a 481% growth in Wegovy's revenues. The company i...

2024-01-11 04:46:33 ET Summary Eli Lilly's weight-loss drug Zepbound, with increasing demand and expected insurance coverage, indicates a significant growth opportunity. Continued success in GLP-1 therapies positions LLY as a leader in the obesity management market, poised for pro...

2024-01-10 12:09:02 ET More on Regeneron Pharmaceuticals Regeneron Pharmaceuticals Inc. (REGN) 42nd Annual JPMorgan Healthcare Conference - (Transcript) Why I Expect Regeneron To Keep Delivering For Investors In 2024 (Upgrade) Regeneron Pharmaceuticals Inc. (REGN) Am...